A Study of Sovilnesib in Subjects With Ovarian Cancer
This is a phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of sovilnesib at different dose levels to establish the optimal dose of sovilnesib in subjects with selected advanced solid tumors.
All Parts: Age ≥ 18 years, ECOG Performance Status ≤ 1, at least 1 site of measu... [+2]
Part 1 only: MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator pheno... [+5]